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Summary
Objectives and design: To determine the most appropriate approach to antibiotic
therapy for osteomyelitis, the medical literature for articles published from 1968 to
2000 was reviewed.
Results: Ninety-three clinical trials in children and adults were identified using
almost every antibiotic class. Most studies were non-comparative and the compara-
tive trials involved relatively few patients. Publications generally did not provide
clinically important information regarding infection staging or classification, surgical
treatment provided, or the presence of orthopedic hardware. The median duration of
follow-up after treatment was only 12 months.
The clinical outcomewas better for acute than chronic osteomyelitis in eight of the
12 studies allowing comparison. In the comparative trials, few statistically significant
differences were observed between the tested treatments. In one small trial, the
combination of nafcillin plus rifampin was more effective than nafcillin alone. In
pediatric osteomyelitis, oral therapy with cloxacillin was more effective than tetra-
cycline in one study, and oral clindamycin was as effective as parenteral anti-
staphylococcal penicillins in another. In several investigations oral fluoroquinolones
were as effective as standard parenteral treatments.
Conclusions: Although the optimal duration of antibiotic therapy remains undefined,
most investigators treated patients for about six weeks. Despite three decades of
research, the available literature on the treatment of osteomyelitis is inadequate to
determine the best agent(s), route, or duration of antibiotic therapy.
# 2005 International Society for Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.* Corresponding author. Tel.: +390444993998; fax: +390444993616.
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The introduction of antibiotics for treating bacterial
infections revolutionized the natural history of
many of these common and deadly diseases. In
the first decades of the antibiotic era, the remark-
able clinical successes with antibiotics led to an
atmosphere of optimism. Based upon these early
successes, Florey and Florey believed that osteo-
myelitis, if treated with antibiotics early, would no
longer be a surgical condition.1 With a mounting
record of clinical failures, however, this optimism
vanished within a few years. By 1968, Bick’s book
reviewing 25 years of experience with antibiotic
treatment led him to conclude that it was invaluable
for eliminating osteomyelitis-related septicemia
and abscesses, but that chronic bone infection could
only be cured with surgery.2
Today, most authorities still believe that chronic
osteomyelitis generally requires both antibiotic and
surgical treatment.3 But, despite continued
research, most aspects of antibiotic treatment for
osteomyelitis are still poorly understood. Data are
sparse about which are the most effective antimi-
crobial agents, for how long, and by what routes
they should be administered for various types of
osteomyelitis. Animal models have been useful in
studying this complex disease, but they cannot
replicate many aspects of human bone infection.4
Thus, the treatment of osteomyelitis is still mostly
based on expert opinions, and no consensus guide-
lines are currently available. Many human trials on
treating osteomyelitis in the last 30 years have been
published, but only the randomized ones have been
systematically reviewed. To supplement the data
from randomized trials with those of non-controlled
trials, the most relevant studies of antibiotic ther-
apy of human osteomyelitis published between 1968
and 2000 are reviewed here.Materials and methods
All clinical studies investigating antibiotic treatment
of osteomyelitis were searched by means of the MED-
LINE search engine (National Library of Medicine,
Washington, DC, USA), applying no language limita-
tion. The terms ‘antibiotic’, ‘antimicrobial’, ‘ther-
apy’, ‘treatment’, ‘bone’, and ‘osteomyelitis’ were
used as keywords in various combinations. Studies
were found that enrolled both pediatric and adult
cases of osteomyelitis, recognizing that the former
are more often hematogenous and the latter more
often contiguous infections. While there are other
commonly used methods of treating osteomyelitis,
e.g., local administration of antibiotics by beads, thisreview was aimed exclusively at systemic antibiotic
therapy.
After reading the abstracts of all retrieved arti-
cles, 120 papers published between January 1968
and January 2001 were identified as possibly being
clinical trials. Trials were selected for analysis only
when they met all of the following criteria: (1) more
than six cases of osteomyelitis were treated; (2)
data about the clinical outcome of the infections
were available; and, (3) a single drug or class of
drugs was used, or, in the case of comparative
studies, in at least one arm of the study. Studies
about ‘bone and joint infections’, or infections
other than osteomyelitis (such as endocarditis,
meningitis) were included only if separate data
about the outcome of bone infection were provided.
Patients identified as having prosthetic joint infec-
tions or infected orthopedic hardware or implants
were not included because these infections gener-
ally require surgical interventions and do not
respond to antibiotic therapy alone. The criterion
for requiring at least six treated cases was arbitra-
rily selected by the authors to avoid considering
small anecdotal studies and because one potentially
relevant comparative trial included only six patients
per arm. Of the 123 papers initially identified, it was
not possible to obtain three of them despite
requests to an inter-library loan service, five were
discarded because they were review articles rather
than clinical trials, five because they pooled the
outcome of different musculoskeletal infections,
five because they enrolled less than six cases of
osteomyelitis, four because of incomplete outcome
data, and seven because they utilized many differ-
ent antibiotics and pooled the outcome of all the
patients.
For each study the following were recorded: the
study design, criteria for diagnosis of osteomyelitis
(clinical, microbiological, radiological, histologi-
cal), name(s) of the antibiotic(s) used, mean age
and sex of the patients, number of pediatric
patients, number of cases treated, number of cases
of long bone osteomyelitis, use of a classification
system, presence of orthopedic hardware and
whether or not it was removed, bone culture iso-
lates, duration of antibiotic treatment, occurrence
of side effects requiring treatment discontinuation,
antibiotic levels in serum and bone, number of
patients undergoing surgery, treatment outcome,
explanation for failure given by the authors, and
duration of follow-up after treatment.
Data were analyzed by means of statistical soft-
ware (Epi Info 2000, Centers for Disease Control and
Prevention, Atlanta, GA, USA). Because different
definitions of outcome were used in the studies
reviewed, the authors devised their own. For each
Antibiotic treatment of osteomyelitis 129study outcomes were defined as follows: ‘cure’ was
the absence of clinical evidence of osteomyelitis
after the follow-up period; ‘failure’ was any out-
come not fulfilling the criteria for ‘cure’. Disconti-
nuation of treatment due to side effects of the study
drug was considered separately.Results
Study features and overall population
enrolled
This review uncovered 93 studies that fulfilled the
selection criteria, with a total of 2476 cases of osteo-
myelitis.5—97 Among these, 17 studies (18%) were
comparative, ten of which were randomized; the
other 76 were non-comparative. In the studies pro-
viding this information, 1090 patients (44%) were
male, and the mean age was 42 years (range 5—66
years, 12.2 [SD]). The mean number of patients
enrolled per study was 26 (range 6—169, 24.5
[SD]); 483 of the cases were pediatric osteomyelitis
and 603 were long bone osteomyelitis.
The authors diagnosed osteomyelitis by various
combinations of clinical, radiological and microbio-
logical findings in 29 studies. The generally acceptedTable 1 Major findings of the studies using anti-staphylo
osteomyelitis.
Author (ref) Drug(s) Durat
treatm
in we
Norden*5 Nafcillin iv vs 6
nafcillin iv + rifampin po
Norden*6 Nafcillin iv vs 6
nafcillin iv + rifampin po
Leder7 Flucloxacillin, continuous iv infusion 6
Bell8 Cloxacillin po or dicloxacillin po 24
Hodgkin9 Cloxacillin po or dicloxacillin po 24
Bryson10 Dicloxacillin po 6
Cole11 Cloxacillin po 6
Hubbard*12 Cloxacillin po 4
vs tetracycline po
Hedstrom*13 Cloxacillin po 24
vs dicloxacillin po
*: Comparative trial; GPC: Gram-positive cocci; GNR: Gram-negat
acute osteomyelitis; iv: intravenous; im: intramuscular; po: o
osteomyelitis.standard criterion for diagnosis, a bone biopsy for
microbiology, was mandatory in only 24 studies, four
of which also required a histological diagnosis. Four
studies required clinical, microbiological, and radi-
ological criteria, whereas in seven studies either
compatible clinical and microbiological criteria, or
microbiological and radiological criteria, were suf-
ficient. Five other studies required just clinical and
radiological criteria, not microbiological confirma-
tion. No criteria for diagnosis were specified in 24
studies.
A classification of the type of osteomyelitis was
provided in 45 (48%) of the studies; ‘acute or
chronic’ was used in 44, the Cierny—Mader classifi-
cation3 was used in one, and a radiological classifi-
cation was used in one. Information about hardware
implantation was available in 12 studies (89
patients) and information about hardware removal
was provided in 11 studies (17 patients). Data about
the duration of the antibiotic treatment were avail-
able in 88 studies; in these, the mean duration of
treatment was 51 days and the median duration of
treatment was 40 days (range 6—180 days, 42.29
[SD]). Serum and bone antibiotic levels were mea-
sured in 32 and 11 studies, respectively. Information
about surgical treatment for osteomyelitis was
available in 27 studies, involving 455 patients. Dura-coccal penicillins for the treatment of staphylococcal
ion of
ent
eks
Duration
of follow-up
in months
Number
of cured
patients/total
Severe
adverse
events
6 7/8 no
6/7
c
24 2/8 no
8/10
c
15 9/11 no
7—30 18/19 1 allergic
reaction
17 9/14 2 hepatotoxicity
60 18/18 no
ch
24 53/64 (83%) no
NA 14/27 no
2/19
ch,c
NA 4/6
6/6 1 with
dicloxacillinch, ad
ive rods; ad: adult; ch: children; c: chronic osteomyelitis; a:
ral; Unless otherwise specified, the studies involved adult
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Table 2 Major findings of the studies of beta-lactam/beta-lactamase inhibitor combinations, carbapenems and
monobactams for treating osteomyelitis.
Author (ref) Drug(s) Commonest
microorganism(s)
Duration of
treatment
(weeks)
Duration of
follow up
(months)
Number
of cured
patients/total
(%)
Severe side
effects
Gentry14 Ticarcillin-clavulanic
acid iv
GPC 4 9 22/36 (61) 2 (bleeding,
urticaria)
Jacobs15 Ticarcillin-clavulanic
acid iv
S. aureus 1 (followed
by 4 weeks
with other
oral drugs)
NA 8/8 no
Siebert*16 Ticarcillin-clavulanic
acid iv
S. aureus 4 22 5/9 no
vs moxalactam iv 4/8
Johnson17 Ticarcillin-clavulanic
acid iv
NA 4—6 NA 24/27 (89) no
Reinhardt*18 Ampicillin-sulbactam GPC 2—6 NA 2/10 no
iv vs clindamycin po 1/3
Loffler*19 Ampicillin-sulbactam GPC and GNR NA 36 5/5 no
iv vs cefotaxime iv 3/5
Kulhanjian*20 Ampicillin-sulbactam GPC and GNR 4 6 5/5
iv vs ceftriaxone iv 4/4
Giamarellou25 Aztreonam iv GNR 6 10 4/7 no
Greenberg26 Aztreonam iv GNR 4 3—15 8/9 no
Scully27 Aztreonam iv P. aeruginosa NA 6—15 5/9 no
Prybil28 Aztreonam iv P. aeruginosa 3 1 13/16 no
Simons29 Aztreonam iv P. aeruginosa 2 12 11/11 no
Conrad29 Aztreonam iv P. aeruginosa 4a 6 5/6 a no
6c 12/12 c
Mogabgab30 Moxalactam iv GPC and GNR 4 NA 7/8 no
MacGregor31 Imipenem iv GPC and GNR 4 11 20/34 (59) no
*: Comparative trial; GPC: Gram-positive cocci; GNR: Gram-negative rods; ad: adult; ch: children; c: chronic osteomyelitis; a:
acute osteomyelitis; iv: intravenous; im: intramuscular; po: oral; Unless otherwise specified, the studies involved adult
osteomyelitis.tion of follow-up was explicit in 73 studies, themean
being 16.6 months (range 1—67 months, median 12).
In 12 studies, the outcome of acute and chronic
cases of osteomyelitis was detailed separately. In
eight (67%) of these studies patients with acute
osteomyelitis achieved a higher cure rate than
patients with chronic osteomyelitis, in three studies
outcome was better in patients with chronic osteo-
myelitis, and in one study the outcomewas similar in
each type. These differences were not statistically
significant in any single study.
Studies by type of antibiotic therapy
Three studies were found that used intravenous
antistaphylococcal penicillins and six studies with
oral antistaphylococcal penicillins (Table 1). Seven
trials investigated a beta-lactam/beta-lactamase
inhibitor, aztreonam was used in six trials, moxa-
lactam and imipenem/cilastatin in one study each(Table 2). There were 30 trials investigating cepha-
losporins, ranging from first generation agents in the
late 1970s to fourth generation agents in the 1990s
(Table 3). Among glycopeptides, teicoplanin was
used in seven studies and vancomycin was adminis-
tered by continuous infusion in one study33
(Table 4). Fluoroquinolones were used in 16 non-
comparative and six comparative trials (Table 5).
Finally, the results of trials of miscellaneous anti-
biotics are reported in Table 6. The pertinent details
of all trials are shown in the tables.Discussion
Osteomyelitis is a relatively common infection, but
a surprisingly small number of comparative trials
about its treatment have been published. Moreover,
most of the studies involve relatively few patients
and are not randomized. The aim of these trials was
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Table 3 Major findings of the studies using cephalosporins for treating osteomyelitis.
Author (ref) Drug(s) Commonest
microorganism(s)
Duration of
treatment
in weeks
Duration of
follow-up
in months
Number
of cured
patients/total
(%)
Severe
adverse
events
Arango46 Cefazolin im(a) S. aureus 4—7 a 6 8/20 a (40)
or cephapirin im (c) 24 c 7/10 c
Fass47 Cefazolin iv S. aureus 4 13 12/13
Liu48 Cefoxitin iv GPC and GNR 2 NA 8/8
Schurman49 Cefoxitin iv GPC and GNR 2 6 6/9
Levine50 Cefamandole iv S. aureus 3 NA 14/16
Bernstein51 Cefamandole iv S. aureus 4 5—23 5/5 a 1
5/9 c
Levine52 Cefamandole iv S. aureus 4 NA 20/25 a (80) NA
separately for
osteomyelitis
22/25 c (88)
LeFrock53 Cefamandole iv S. aureus 4 NA 12/12
Nelson54 Cefamandole iv
and cefaclor
(sequentially)
S. aureus 3 NA 22/23 (96) 0
Temple55 Cefoperazone iv NA 4 NA 7/9
Biehl56 Cefoperazone iv S. aureus 1 NA 18/24 (75)
LeFrock57 Cefotaxime iv GPC 3 NA 6/7 a
25/32 c (78)
Mader58 Cefotaxime iv S. aureus 4 12 23/25 a (92)
24/27 c (89)
Mader59 Cefotaxime iv S. aureus 6 6 a 21/22 a (96) 2 neutropenia
at end of
treatment
7 c 38/46 c (83)
LeFrock60 Cefotaxime iv GPC 4 12—24 12/12 a
17/20 c (85)
Jacobs61 Cefotaxime iv GPC 2 NA 23/24 (96)
Mader62 Ceftizoxime iv GPC and GNR 6 1—12 13/14 4
Gomis63 Cefotaxime iv E. coli 4 6 40/50 (80)
Dutoy64 Ceftazidime iv P. aeruginosa 4 6 7/7 a
11/14 c
Eron65 Ceftazidime iv P. aeruginosa 6 NA 4/8 1 leukopenia
Bach66 Ceftazidime iv P. aeruginosa 4 6 a 9/11 a
12 c 7/15 c
De Bastiani67 Ceftazidime iv GPC and GNR 4 12—48 9/10
Giamarellou68 Ceftriaxone iv NA 3 NA 3/7
Yogev69 Ceftriaxone iv GPC and GNR 4 2 6/6
Pottage70 Cefsulodin iv P. aeruginosa 4 12 3/8 3
Routman71 Cefsulodin iv P. aeruginosa 24 12 12/16
Lucht72 Cefsulodin iv P. aeruginosa 24 36 11/15
Sheftel73 Cefmenoxime iv GPC 6 12 6/15
Jauregui74 Cefepime iv S. aureus, GPC, and GNR 4 12 19/23 (83)
Kunkel75 Cefonicid iv
or im
S. aureus 6 3—13 12/12
*: Comparative trial; GPC: Gram-positive cocci; GNR: Gram-negative rods; ad: adult; ch: children; c: chronic osteomyelitis; a:
acute osteomyelitis; iv: intravenous; im: intramuscular; po: oral; Unless otherwise specified, the studies involved adult
osteomyelitis.generally to determine if a ‘new’ drug was at least
equivalent to an established treatment, in order to
justify using it for treating bone infections. Most of
the trials failed to detect statistically significant
differences between the two groups, thus providinglittle understanding about the relative effective-
ness of various regimens for treating osteomyelitis.
Another limitation of the available literature is that
trials involving ‘bone and joint infections’ include a
heterogeneous spectrum of diseases, with different
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Table 4 Major findings of the studies using glycopeptides for treating staphylococcal osteomyelitis.
Author (ref) Drug(s) Duration of
treatment
(weeks)
Duration of
follow-up
(months)
Number of
cured
patients/total
(%)
Severe
adverse
events
Bernard33 Vancomycin, iv
continuous infusion
24 14 10/15 no
de Lalla34 Teicoplanin iv NA 3 6/8 no
Marone35 Teicoplanin iv NA 12 2/7 no
Greenberg36 Teicoplanin iv 6 12 10/14 no
Weinberg37 Teicoplanin iv 6 6 3/14 a no
8/20 c (40)
Graninger38 Teicoplanin iv,
three times weekly
8 12 18/44 (41) no
LeFrock39 Teicoplanin iv 6 6 76/80 a (95) 24 patients
62/65 c (95)
Testore40 Teicoplanin im 24 12 72/76 (95) no
*: Comparative trial; GPC: Gram-positive cocci; GNR: Gram-negative rods; ad: adult; ch: children; c: chronic osteomyelitis; a:
acute osteomyelitis; iv: intravenous; im: intramuscular; po: oral; Unless otherwise specified, the studies involved adult
osteomyelitis.prognoses. For example, the cure rate with anti-
biotics alone of pediatric hematogenous osteomye-
litis is much higher than that of a prosthetic joint
infection. Thus, in this review only studies that
provided separate outcomes for patients with osteo-
myelitis are included. Moreover, to avoid anecdotal
information, trials involving fewer than six patients
were excluded. Finally, it has been noted that stu-
dies reporting poor outcomesmay be less likely to be
published, introducing the possibility of publication
bias. While an exhaustive literature search was not
performed, it is believed that these methods are
likely to have revealed the best quality published
papers. The similarity of the reported cure rates for
the various studies suggests that the results are
likely to be accurate and generalizable.
Taking into account all the variables in patients
with osteomyelitis (e.g., pathogenesis, localization,
microbial etiology, surgical treatment) would
require analyzing a large number of cases. A recent
systematic review of the use of antibiotics for
treating bone and joint infection98 included only
controlled trials, but did not separate patients
with bone versus joint infections. The authors
concluded that there is little high quality evidence
on the relative effectiveness of various regimens
of antibiotic therapy for osteomyelitis or septic
arthritis. Furthermore, by excluding uncontrolled
studies, they ignored most of the trials on osteo-
myelitis. In this literature review, 82% of the pub-
lished osteomyelitis studies were non-comparative.
Thus, to capture all of the available data, both
comparative and non-comparative studies have
been reviewed.Another problem for studies on osteomyelitis is
that of defining the outcome. Virtually every study
offered a different definition, using terms such as
‘cure’, ‘improvement’, ‘eradication’, ‘failure’, and
‘recurrence’, each having a different meaning.
Using the Infectious Disease Society of America
(IDSA) guidelines on the requirements of human
trials on osteomyelitis,99 a common definition was
adopted that reflects what can be expected from a
course of treatment with antibiotics: a favorable
outcome means that the patient is clinically free of
disease at the end of the follow-up period. Further-
more, clinical trials should have at least a one-year
follow-up period. Unfortunately, many studies did
not have this minimum follow-up. Moreover, the
duration of follow-up varied markedly, making it
difficult to compare data from different studies
on the same antibiotic.
Another problem is the disease classification
schemes used in the studies. About half of the
reviewed studies did not use any osteomyelitis clas-
sification system. In the others, the most commonly
used classification was simply ‘acute’ versus
‘chronic’. Unfortunately, most authors did not pro-
vide definitions of acute and chronic osteomyelitis
and when given, the threshold between acute and
chronic ranged from 20 days to six months. The
hallmark of chronic osteomyelitis is the presence
of necrosis on bone histology. Since this finding may
be present early on during the natural history of the
disease, classification into acute versus chronic by
duration of disease is inaccurate.100 Although sev-
eral classifications of osteomyelitis have been advo-
cated,100 none is universally accepted.
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Table 5 Major findings of the studies using fluoroquinolones for treating osteomyelitis.
Author (ref) Drug Commonest
microorganism
(s)
Duration
of treatment
Duration
of
follow-up
Number
of cured
patients/
total (%)
Severe
side
effects
Non-comparative Trials:
Ramirez76 Ciprofloxacin po GPC and GNR 6 NA 5/8 0
Scully77 Ciprofloxacin po P. aeruginosa 6 NA 4/6 0
Slama78 Ciprofloxacin po GNR 11 NA 22/30 (73) 0
Gilbert79 Ciprofloxacin po GNR 6—14 7—21 13/20 (65) 0
Trexler Hessen80 Ciprofloxacin po P. aeruginosa 9 10 22/24 (92) 2
Gudiol81 Ciprofloxacin po NA 8 11 15/20 (75) 0
Lopez82 Ciprofloxacin po NA NA NA 1/8
Yamaguti83 Ciprofloxacin po GPC and GNR 23 12 13/17 (76)
Dan84 Ciprofloxacin po P. aeruginosa 12 27 19/22 (86)
Mac Gregor85 Ciprofloxacin po NA 20 18 11/18 (61) 1
Ketterl86 Ofloxacin po S. aureus 3 6 113/115 (98)
Kannellakopoulou87 Ofloxacin po GNR 24 6 15/20 (75)
Eron88 Ofloxacin po GPC and GNR 24 12 6/6
Liu89 Fleroxacin po NA 4 3 4/7
Dellamonica90 Oral fluoroquinolones S. aureus 24 36 29/39 (74)
Greenberg91 Oral fluoroquinolones S. aureus 8 12 16/27 (59) 3
Comparative Trials
Giamarellou*92 Pefloxacin iv or po vs
ceftazidime iv
NA 25 12 7/8
5/6
Gentry*93 Ofloxacin po vs cefazolin
iv or ceftazidime iv
Polymicrobial 8 18 14/19 no
12/14
Gomis*94 Ofloxacin po vs
Imipenem-cilastatin iv
NA 4 6 7/11 1
Imipenem
7/10
Gentry*95 Ciprofloxacin po vs
nafcillin po
S. aureus 7 12 24/31 (77)
22/28 (79)
Mader*96 Ciprofloxacin po vs
nafcillin iv +
clindamycin po
GPC 6 32 11/14
10/12
Greenberg*97 Ciprofloxacin po vs
parenteral treatments
Enterobacteriaceae 4 13 6/14
11/16
*: Comparative trial; GPC: Gram-positive cocci; GNR: Gram-negative rods; ad: adult; ch: children; c: chronic osteomyelitis; a:
acute osteomyelitis; iv: intravenous; im: intramuscular; po: oral; Unless otherwise specified, the studies involved adult
osteomyelitis.Some studies were restricted to specific causa-
tive organisms, based on the spectrum of the study
drug. Most of infections were monomicrobial, but
cases of polymicrobial osteomyelitis occurred, espe-
cially associated with a diabetic foot infection.
Since it is not known if cases of osteomyelitis due
to different microbial species have different out-
comes, it would probably be more accurate to
restrict antibiotic trials to a single microbial
species or category. Very few studies specified the
antimicrobial susceptibility patterns of the isolatedorganisms, e.g., the prevalence of methicillin-resis-
tant Staphylococcus aureus or Gram-negative
organisms with extended spectrum beta-lacta-
mases.
Information about surgical treatment for osteo-
myelitis, and the presence of surgically implanted
bone hardware (and whether or not it was removed)
was not provided in most studies. These factors
greatly influence the outcome of treatment. Most
authorities believe that an incompletely debrided
bone infection is prone to treatment failure, no
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Table 6 Major findings of the studies using miscellaneous antibiotics for treating osteomyelitis.
Author (ref) Drug(s) Commonest
microorganism(s)
Duration of
treatment
(weeks)
Duration of
follow-up
(months)
Number
of cured
patients/
total (%)
Severe
side
effects
Beauvais21 Pristinamycin po S. aureus 6—12 18 25/31 (81) ch 6 patients
Feigin22 Clindamycin po S. aureus 6 a 24 13/19 a no
24 c 6/6 ch
Rodriguez23 Clindamycin po S. aureus 10 15 28/29 (97) ch 1 allergy
Kaplan24 Clindamycin po, S. aureus 6 12 11/12 no
vs nafcillin iv 9/13
Saengnipanthkul41 Cotrimoxazole po S. aureus 4—8 12 30/66 (45) no
vs oral penicillins 22/45 (49)
Sanchez42 Cotrimoxazole po
+ rifampin po
S. aureus 4 43 21/27 (78) 3
Fernandez43 Fosfomycin po S. aureus 3 48 29/37 (78) no
Hierolzer44 Fusidic acid po S. aureus NA NA 54/72 (75) no
Coombs45 Fusidic acid po Coagulase
negative
staphylococci
3 NA 19/20 (95) no
*: Comparative trial; GPC: Gram-positive cocci; GNR: Gram-negative rods; ad: adult; ch: children; c: chronic osteomyelitis; a:
acute osteomyelitis; iv: intravenous; im: intramuscular; po: oral; Unless otherwise specified, the studies involved adult
osteomyelitis.matter what antibiotic therapy has been
used.3,100,103 Radical debridement of infected or
necrotic bone is even more important in the
compromised host.101 Therefore, information is
req-uired about any surgical treatment provided
in a study about antibiotic treatment of osteomye-
litis.
Duration of antibiotic therapy is also an impor-
tant issue when treating osteomyelitis. There is
little published evidence upon which to determine
the most effective duration. In the reviewed papers
two major trends were found: most treated the
patients for about six weeks, while a minority trea-
ted patients for about six months. Data from animal
models show that bacteria can be cultured from
infected bone even after two weeks of appropriate
antibiotic therapy;102 therefore, treatment for four
to six weeks has usually been advised.3,103 One
retrospective survey of clinical cases supported a
shorter duration of treatment;104 there is no pub-
lished evidence of better results with longer treat-
ment. Outcomes by treatment duration could not be
analyzed as prolonged therapy was administered in
only seven of 95 studies.
Considering the difficulties of conducting a
human trial, animal models create more controlled
conditions for comparing the efficacy of different
antibiotics. Animal trials allow control over the
type, duration and severity of disease, any surgical
debridement provided, the etiologic agents, and the
duration of follow-up. When lacking adequate evi-
dence on drug efficacy, antibiotics for osteomyelitismust often be chosen on the basis of their safety
profile. Patient adherence to the treatment, which
is better with simplified regimens, must also be
considered.
Available evidence suggests that oral antibiotic
therapy can be as effective as parenteral treat-
ments. The evidence is strongest for fluoroquino-
lones, because they were used in more recent, well-
planned comparative studies. Oral clindamycin has
also compared favorably with parenteral regimens
in one trial.24 These favorable results largely derive
from the excellent bioavailability and bone pene-
tration of these classes of antibiotics. Oral treat-
ments have the advantage of reduced duration of
hospitalization and health care costs. For organisms
resistant to oral drugs, outpatient parenteral anti-
biotic treatment (OPAT) has been successfully
employed.105 Newer methods of using parenteral
therapy are also available. Vancomycin has been
administered by continuous infusion and teicoplanin
has been administered three times weekly to treat
staphylococcal osteomyelitis.33,38 Indeed, the latter
approach appears more feasible and deserves con-
sideration in those countries where teicoplanin is
available.
Cephalosporins were used in many of the osteo-
myelitis studies and were generally found to be
effective. Most of the studies used intravenous
cephalosporins, although oral agents, e.g., cepha-
lexin, are often used clinically. Once-daily adminis-
tered drugs, such as ceftriaxone, are preferred,
especially for outpatient therapy.105 As new oral
Antibiotic treatment of osteomyelitis 135regimens become available, and the prevalence of
methicillin-resistant staphylococci increases, intra-
venous cephalosporins are likely to become a less
widely used treatment of osteomyelitis. New agents
with good oral bioavailability, high bonepenetration,
and activity against MRSA (e.g., linezolid) have great
promise,106 but must be tested in clinical trials.107
The published reports on the antibiotic treatment
of osteomyelitis have not provided information
on most key treatment issues. All the antibiotic
classes listed in this review have demonstrated
efficacy in treating osteomyelitis, but well-designed
comparative studies to elucidate the most appro-
priate regimens are lacking. Therefore, the choice
of anti-biotic, unless limited by the sensitivity
of the etiologic organism(s), should be based
mostly on the safety of various agents for prolonged
use, and the cost and practicality of the chosen
regimen. Additional, properly designed, studies
are needed to ascertain the best agent(s), route,
and duration of antibiotic treatment for patients
with osteomyelitis.Acknowledgments
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